Elicio Therapeutics ( (ELTX) ) has issued an announcement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Elicio Therapeutics has announced updated results from its ELI-002 Phase 1 AMPLIFY-201 study, which were shared at the ESMO Immuno-Oncology Congress 2024. The ELI-002 vaccine targets KRAS mutations and has shown promising immunogenicity and durability in cancer patients, with significant T cell responses and reduced risk of relapse or death. Elicio has raised $33 million in new capital to fund operations through the anticipated Phase 2 interim analysis in 2025, and is working towards Phase 3 readiness by early 2026.
More about Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel lymph node-targeted cancer immunotherapies. The company’s primary product candidates include cancer vaccines and immunomodulators designed to harness the lymph nodes’ natural ability to amplify immune responses, with a particular focus on targeting KRAS mutations in solid tumors.
YTD Price Performance: -36.21%
Average Trading Volume: 22,564
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $57.41M
See more data about ELTX stock on TipRanks’ Stock Analysis page.
